KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Inventory: 2012-2024

Historic Inventory for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2024 value amounting to $54.3 million.

  • Supernus Pharmaceuticals' Inventory rose 24.10% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.4 million, marking a year-over-year increase of 24.10%. This contributed to the annual value of $54.3 million for FY2024, which is 29.86% down from last year.
  • Supernus Pharmaceuticals' Inventory amounted to $54.3 million in FY2024, which was down 29.86% from $77.4 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Inventory high stood at $91.5 million for FY2022, and its period low was $48.3 million during FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Inventory averaged around $74.4 million, with its median value being $77.4 million (2023).
  • Its Inventory has fluctuated over the past 5 years, first surged by 81.48% in 2020, then decreased by 29.86% in 2024.
  • Supernus Pharmaceuticals' Inventory (Yearly) stood at $48.3 million in 2020, then skyrocketed by 77.88% to $86.0 million in 2021, then increased by 6.49% to $91.5 million in 2022, then dropped by 15.44% to $77.4 million in 2023, then dropped by 29.86% to $54.3 million in 2024.